Universal HCV treatment costeffective in Italy

Universal HCV treatment costeffective in Italy PharmacoEconomics & Outcomes News 784, p30 - 12 Aug 2017 Universal HCV treatment cost effective in Italy Universal treatment of hepatitis C virus (HCV) at any fibrosis stage appears to be cost effective in Italy, compared with treatment of prioritised patients and those with fibrosis stage F3 (policy 2), according to findings of a study published in Hepatology. A Markov model of liver disease progression populated with data from the PITER cohort (May 2014–December 2015) was used to evaluate the cost effectiveness of direct-acting antiviral (DAA) treatment in 8125 DAA-naıve patients with chronic HCV, under a universal policy versus policy 2 (prioritised/F3), from the perspective of the Italian National Health Service over a lifetime time horizon. The assumed treatment cost for DAA was €15 000 per patient. In the base-case analysis in Italy, universal treatment was estimated to gain 93 131 QALYs at a cost of €301 788 399, while policy 2 gained 89 490 QALYs at a cost of €269 841 561, resulting in an estimated incremental cost-effectiveness ratio (ICER) for universal DDA treatment versus policy 2 of €8775 per QALY gained. The ICER was below the willingness-to-pay (WTP) threshold of €20 000–€40 000 per QALY gained. In probabilistic sensitivity analysis, ICERs were below the lower WTP threshold in 94% of simulations and below the upper threshold in 97% of simulations. In a European scenario analysis, assuming a treatment cost of €30 000 and using data from France, Germany, Italy, Romania and the UK, the ICER for universal treatment was €19 542 per QALY gained. ICERs ranged from €9108 per QALY gained at a DDA cost of €15 000 to €26 498 per QALY gained at a DDA cost of €40 000. "Extending HCV treatment to patients at any fibrosis stage improves health outcomes and is cost effective. Cost-effectiveness significantly increases when lowering treatment prices in early fibrosis stages," concluded the authors. At DDA prices less than 75% of the €15 000 base price, universal treatment in patients with fibrosis stage F0–F2 became dominant (more effective and less costly) compared with prioritised treatment. Kondili LA, et al. Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort. Hepatology : 24 Jul 2017. Available from: URL: http://doi.org/10.1002/hep.29399 803262336 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Universal HCV treatment costeffective in Italy

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial